Predictors of noncompliance in patients with schizophrenia.
about
The use of amisulpride in the treatment of acute psychosisDiscontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs.Medication adherence in schizophreniaCurrent Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive ReviewThe effect of chronic antipsychotic drug on hypothalamic expression of neural nitric oxide synthase and dopamine D2 receptor in the male ratChanges in body weight and psychotropic drugs: a systematic synthesis of the literatureBaseline patient characteristics and mortality associated with longitudinal intervention compliance.Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice.Medication adherence among older adults with schizophrenia.Psychotic disorders in children and adolescents: a primer on contemporary evaluation and managementSustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational studyBaseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence.Impact of depression and social support on nonadherence to antipsychotic drugs in persons with schizophrenia in Thailand.Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations.Trait and state attributes of insight in first episodes of early-onset schizophrenia and other psychoses: a 2-year longitudinal studyThe role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysisRisperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada.Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trialThe heterogeneity of antipsychotic response in the treatment of schizophrenia.Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).Neurobiology of insight deficits in schizophrenia: An fMRI studyThe prevalence of self-reported underuse of medications due to cost for the elderly: results from seven European urban communitiesBaseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety studyThe Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.Using the theory of planned behavior to improve treatment adherence in Mexican Americans with schizophreniaPresent and future of secondary prevention after an acute coronary syndrome.Second generation antipsychotics improve sexual dysfunction in schizophrenia: a randomised controlled trial.Effects of auricular acupressure on body weight parameters in patients with chronic schizophrenia.Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders.Mobile.net: Mobile Telephone Text Messages to Encourage Adherence to Medication and to Follow up With People With Psychosis: Methods and Protocol for a Multicenter Randomized Controlled Two-Armed Trial.Perception of service satisfaction and quality of life of patients living with schizophrenia in Lagos, Nigeria.Use of depot antipsychotic medications for medication nonadherence in schizophreniaThe influence of clinical, treatment, and healthcare system characteristics on psychiatric readmission of adolescents.A New Psychosocial Tool for Gaining Patient Understanding and Acceptance of Long-acting Injectable Antipsychotic Therapy.Insight, neurocognition, and schizophrenia: predictive value of the wisconsin card sorting test.Evaluation of a discharge medication service on an acute psychiatric unit.Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia.Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia.
P2860
Q24683055-FFCC5521-2FCE-41ED-994B-85687EE73D3EQ25257471-B297BE26-6000-479D-A620-FAB1DD1A7AD6Q26823655-E165FA8C-1C95-4AAA-B0E7-A61AF98AC12BQ28079821-0F5B8E12-DF31-43AF-8F63-F0FEF55149BFQ28482341-6E86648B-3011-4917-9584-0E0F67DF41BAQ28728401-1479ECDD-0CC9-4791-9EF4-724A47619C08Q33605209-862760F1-0D79-4F47-9B28-D50B68BE5AFDQ33873068-6E143508-6F46-4FF1-B136-36E23C24F0ABQ33893240-74C62036-ABFA-4FD6-B039-F14F28846C4FQ33975802-68D43E64-30CB-44F6-BC7B-01E487888062Q34003858-59BFD5B9-67B4-48AF-8786-1082E0852D23Q34144373-1A70AECF-EC52-43AC-BB01-545F5B33D131Q34231559-DA324845-64D0-4426-B513-C77CA39381C7Q34386881-09240E92-A91C-45F2-9990-26C7BB11B51DQ34415868-549D505F-E292-4530-B86A-AA2729E81AACQ34418847-B75DE585-3BF9-48D9-9A71-8A856F7BC11CQ34486175-DDF75D5F-AE4B-4AF2-ADFC-267AE8EDC668Q34661011-292415AA-9FBA-4A70-BE74-27B16617CAD7Q34746791-83B82193-2BDA-4F2E-A95A-B23399AF375CQ34785866-8905DFCD-019E-436A-AB28-3BA1B504B9E0Q34831046-E78D008D-CB7B-44C2-BF85-34C68A0DE2B0Q34966395-3AF2DBCC-5C41-49E2-979F-8614352C9CE0Q35688564-51093DBF-C349-4340-A4D1-A89AEDA892EAQ35789487-8F5CFF4C-0D26-4C96-94CF-DE25BCE50D4DQ35841195-8DD5BED5-98F1-40A6-9D52-3954DF2E3854Q36059843-D05F311E-83C2-417B-9253-56BC2172989FQ36068636-7DD2934E-7021-409E-8776-CAEB0EB3376EQ36118008-0C141DFB-7785-40F3-A159-0A2182E0F432Q36192428-1E3F1279-537B-4D16-A538-01D000EF0107Q36241602-862319C4-B2CF-4689-94B2-E58E0D26A424Q36700337-7ACC8861-608E-47F4-9C2C-E73A53485870Q36765328-F3706717-AA3D-4952-B0F0-3C290DFD500EQ36768460-71972B54-40D5-458A-B839-44DA445F7735Q36842947-92BA3B8A-05FF-4C06-8EFF-43BCB6D13B84Q37000585-C8E685E6-CFD9-4FD2-B0C6-02C188549F3CQ37272606-90AE31A4-E20C-4F54-A584-0E7F9BD7B098Q37328651-45E06E2C-3CDD-4F1B-BE05-90A8BDE9CF37Q37339978-5C0DB35C-EDE8-486E-87FB-02DF000E7D4AQ37425367-3722E976-7AA5-45C5-AA6D-E8D8F6091030Q37596280-16A6D0DC-8433-4B8A-89F8-6007941C2B7E
P2860
Predictors of noncompliance in patients with schizophrenia.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Predictors of noncompliance in patients with schizophrenia.
@en
type
label
Predictors of noncompliance in patients with schizophrenia.
@en
prefLabel
Predictors of noncompliance in patients with schizophrenia.
@en
P356
P1476
Predictors of noncompliance in patients with schizophrenia
@en
P2093
Diana O Perkins
P304
P356
10.4088/JCP.V63N1206
P577
2002-12-01T00:00:00Z